[go: up one dir, main page]

MX2014004960A - Composiciones liposomales combinadas para terapia contra el cancer. - Google Patents

Composiciones liposomales combinadas para terapia contra el cancer.

Info

Publication number
MX2014004960A
MX2014004960A MX2014004960A MX2014004960A MX2014004960A MX 2014004960 A MX2014004960 A MX 2014004960A MX 2014004960 A MX2014004960 A MX 2014004960A MX 2014004960 A MX2014004960 A MX 2014004960A MX 2014004960 A MX2014004960 A MX 2014004960A
Authority
MX
Mexico
Prior art keywords
combinational
cancer therapy
liposome compositions
liposome
therapeutic
Prior art date
Application number
MX2014004960A
Other languages
English (en)
Other versions
MX360391B (es
Inventor
Yangjun
Stephen H Wu
Cliff J Herman
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of MX2014004960A publication Critical patent/MX2014004960A/es
Publication of MX360391B publication Critical patent/MX360391B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona los métodos para la distribución de agentes terapéuticos a un sujeto, utilizando sistemas liposomales de componentes múltiples. Los métodos incluyen la administración de un liposoma terapéutico que contiene un agente activo, seguido por una administración de un liposoma de ataque que induce la liberación de los agentes desde el liposoma terapéutico.
MX2014004960A 2011-10-31 2012-10-31 Composiciones liposomales combinadas para terapia contra el cancer. MX360391B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553786P 2011-10-31 2011-10-31
PCT/US2012/062635 WO2013066903A1 (en) 2011-10-31 2012-10-31 Combinational liposome compositions for cancer therapy

Publications (2)

Publication Number Publication Date
MX2014004960A true MX2014004960A (es) 2014-06-05
MX360391B MX360391B (es) 2018-10-31

Family

ID=47146747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004960A MX360391B (es) 2011-10-31 2012-10-31 Composiciones liposomales combinadas para terapia contra el cancer.

Country Status (12)

Country Link
US (4) US9370489B2 (es)
EP (2) EP2773426B1 (es)
JP (4) JP6143767B2 (es)
KR (1) KR20140097215A (es)
CN (1) CN104023793B (es)
BR (1) BR112014010291A2 (es)
CA (1) CA2852564A1 (es)
ES (1) ES2694154T3 (es)
IL (2) IL232344B (es)
MX (1) MX360391B (es)
RU (1) RU2640934C2 (es)
WO (1) WO2013066903A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5872466B2 (ja) * 2009-07-17 2016-03-01 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ 放射性核種含有ナノ粒子を製造するための封入方法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SMT201800264T1 (it) * 2013-03-15 2018-07-17 Translate Bio Inc Potenziamento sinergico del rilascio di acidi nucleici attraverso formulazioni miscelate
JP2014227338A (ja) * 2013-05-17 2014-12-08 キヤノン株式会社 インドシアニングリーン含有粒子およびその製造方法
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
CA2976526A1 (en) * 2015-02-13 2016-08-18 Trendmed Co., Ltd. Compositions and methods of tumor treatment utilizing nanoparticles
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
US20180243217A1 (en) * 2015-03-17 2018-08-30 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
EP3277264A4 (en) * 2015-04-02 2018-07-18 The Research Foundation for the State University of New York Serum-stable compositions and methods for light-triggered release of materials
DK3350157T3 (da) 2015-09-17 2022-02-14 Modernatx Inc Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
CN111437259A (zh) * 2015-11-02 2020-07-24 富士胶片株式会社 包含吉西他滨或其盐的脂质体组合物
US12364661B2 (en) 2015-11-20 2025-07-22 The Regents Of The University Of California Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
WO2017104840A1 (ja) * 2015-12-18 2017-06-22 メディギア・インターナショナル株式会社 生体分解性腫瘍封止剤
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
KR101630397B1 (ko) * 2015-12-31 2016-06-24 한국과학기술원 항암제-인도시아닌 그린-리포좀 복합체를 포함하는 암 치료용 조성물
US11517539B2 (en) 2016-02-15 2022-12-06 University Of Georgia Research Foundation, Inc. IPA-3-loaded liposomes and methods of use thereof
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN106474057A (zh) * 2016-12-02 2017-03-08 中国药科大学 一种奥沙利铂热敏长循环脂质体的蔗糖溶液制剂及其制备方法
SG11201906539YA (en) * 2017-01-18 2019-08-27 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes increase targeting of mitotic cells
SI3596042T1 (sl) 2017-03-15 2022-04-29 Modernatx, Inc. Kristalne oblike amino lipidov
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
CN110662532A (zh) 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US10925831B2 (en) * 2017-08-28 2021-02-23 Wake Forest University Liposomal formulations of platinum-acridine anticancer agents and methods thereof
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019084290A1 (en) * 2017-10-25 2019-05-02 Arizona Board Of Regents On Behalf Of The University Of Arizona COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACEUTICAL AGENTS
US10606661B2 (en) * 2017-12-15 2020-03-31 Rubrik, Inc. On-demand provisioning of customized developer environments
JP7364561B2 (ja) 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
MA53652A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg de haute pureté et leurs utilisations
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
WO2020115171A1 (en) * 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Immunogenic compositions
RU2706427C1 (ru) * 2018-12-27 2019-11-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
JP7253735B2 (ja) 2019-07-02 2023-04-07 パナソニックＩｐマネジメント株式会社 通過可否判定装置、通過管理システム、通過可否判定方法、及び、コンピュータプログラム
AU2020349613B2 (en) 2019-09-19 2025-11-13 Danmarks Tekniske Universitet Immune stimulating micelle composition
AR120080A1 (es) 2019-09-19 2022-02-02 Modernatx Inc Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
US20220364139A1 (en) * 2019-09-24 2022-11-17 Pataigin, Llc Methods for determining growth and response
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
WO2022038605A1 (en) * 2020-08-20 2022-02-24 Bionanosim (Bns) Ltd Lipid delivery systems for delivery of oxaliplatin palmitate acetate
KR102560135B1 (ko) 2020-12-04 2023-07-27 가톨릭대학교 산학협력단 표적 치료제의 효과적인 전달을 위한 다기능성 리포좀 조성물
WO2022171777A1 (en) 2021-02-12 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for prognosis and treating a patient suffering from cancer
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
JP2024509938A (ja) 2021-03-08 2024-03-05 アイジーン インコーポレイテッド ＳＡＲＳ－ＣｏＶ－２予防用ワクチン組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
CA2252055C (en) 1996-04-11 2007-01-16 The University Of British Columbia Fusogenic liposomes
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US7273620B1 (en) * 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US7149468B2 (en) 2002-07-25 2006-12-12 The Mcgraw-Hill Companies, Inc. Methods for improving certainty of test-taker performance determinations for assessments with open-ended items
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CA2526278A1 (en) 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
US20070248541A1 (en) * 2003-12-01 2007-10-25 Mitsubishi Pharma Corporation Liposome
TWI262798B (en) * 2003-12-31 2006-10-01 Ind Tech Res Inst Liposome and drug deliver system
US20110020434A1 (en) 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
WO2007049279A2 (en) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A liposomal combination and uses thereof

Also Published As

Publication number Publication date
JP2019023243A (ja) 2019-02-14
CN104023793A (zh) 2014-09-03
ES2694154T3 (es) 2018-12-18
JP2017101085A (ja) 2017-06-08
IL258740B (en) 2019-01-14
IL258740A (en) 2018-06-28
JP2014532665A (ja) 2014-12-08
WO2013066903A1 (en) 2013-05-10
BR112014010291A2 (pt) 2017-04-18
CN104023793B (zh) 2017-11-24
RU2014120216A (ru) 2015-12-10
JP6549172B2 (ja) 2019-07-24
US20130115273A1 (en) 2013-05-09
US20160338958A1 (en) 2016-11-24
EP2773426A1 (en) 2014-09-10
EP2773426B1 (en) 2018-08-22
US20190175505A1 (en) 2019-06-13
EP3424564A1 (en) 2019-01-09
US10213385B2 (en) 2019-02-26
US9370489B2 (en) 2016-06-21
CA2852564A1 (en) 2013-05-10
JP2019123753A (ja) 2019-07-25
RU2640934C2 (ru) 2018-01-12
IL232344A0 (en) 2014-06-30
JP6143767B2 (ja) 2017-06-07
KR20140097215A (ko) 2014-08-06
US20180015039A1 (en) 2018-01-18
US9717686B2 (en) 2017-08-01
MX360391B (es) 2018-10-31
IL232344B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
MX360391B (es) Composiciones liposomales combinadas para terapia contra el cancer.
TR201816986T4 (tr) Terapötik ajan iletim formülasyonlarına yönelik lipitler.
GB201118656D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
NZ732777A (en) Ionizable cationic lipid for rna delivery
MX366899B (es) Nuevos compuestos.
IL233031B (en) Complete mini-cells derived from bacteria for the delivery of medicinal substances to brain tumors
EA201290712A1 (ru) Альфа-излучающие комплексы
IN2014DN10670A (es)
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
MY168300A (en) Pharmaceutical Composition for Inhalation
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
PH12014500381A1 (en) Therapeutic methods
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
PH12014502065A1 (en) Vesicular formulations
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents
PH12014500432A1 (en) Stable compositions and methods for preparing the same
PH12014500979A1 (en) Therapeutic combination of memantine and baclofen and pharmaceutical composition containing them
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
UA56535U (ru) Способ лечения функциональной кисты после резекции яичника

Legal Events

Date Code Title Description
FG Grant or registration